Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02737865
Other study ID # 2015-10-134-003
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 2016
Est. completion date April 25, 2019

Study information

Verified date December 2019
Source Samsung Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Focal nodular hyperplasia (FNH) in liver is the second common benign hepatic tumor. It usually shows hypervascular mass on imaging studies and it is not easy to differentiate with other hypervascular malignant tumor. For diagnosis of FNH, contrast-enhanced ultrasonography (US) has been used to detect 'spoke-wheel sign', which can be typically seen in FNH. However, temporal window of vascular phase using contrast-enhanced US (CEUS) is very short (about 10 sec) and coordination of patient`s respiration during US exam is absolutely needed. Thus, the investigators will use Superb-Microvascular imaging (SMI, Toshiba, Japan) for detection of 'spoke-wheel sign' in patients with proven FNH, which enable to detect slow micro vascular flow without using CEUS.

First, to compare the detection rate of 'spoke-wheel sign' between CEUS using sonazoid (Perfluorobutane, GE healthcare) and SMI.

Second, to compare the accuracy of size measurement between gray-scale US and SMI (reference standard: CEUS using sonazoid.)


Description:

1. To evaluate the detection rate of 'spoke-wheel sign' on CEUS using sonazoid and SMI (primary outcome).

Each US findings during exam for patients with FNH were recorded by radiologist. The results were interpreted by consensus using 4 scale bar.

0. Absence of 'spoke-wheel sign'

1. Mild suspicious of 'spoke-wheel sign'

2. Highly suspicious of 'spoke-wheel sign'

3. Definite "spoke-wheel sign'

2. To evaluated the accuracy of size measurement for FNH on gray-scale US and SMI (reference standard: CEUS using sonazoid).

To calculate the measurement error between each method and CEUS using sonazoid on US images using measurement of maximum diameter of tumor.

3. Sample size calculation according to the primary outcome.

Expecting the detection rate of "spoke-wheel sign" on SMI, 20% (known detection rate on CEUS using sonazoid, 23.5%), a sample size of 62 patients was required using 95% confidence interval.


Recruitment information / eligibility

Status Completed
Enrollment 62
Est. completion date April 25, 2019
Est. primary completion date April 25, 2019
Accepts healthy volunteers No
Gender All
Age group 20 Years to 70 Years
Eligibility Inclusion Criteria:

1. Patients with biopsy or imaging proven focal nodular hyperplasia

Exclusion Criteria:

1. Pregnant women

2. Patient`s age > 70

3. Egg allergy

4. Breast-feeding women

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sonazoid
Sonazoid: Commercially available contrast material for ultrasonography
Device:
Superb-Microvascular imaging
Superb-Microvascular imaging: new sonographic software technique on ultrasonography to detect low-vascular flow without use of contrast media for ultrasonography

Locations

Country Name City State
Korea, Republic of Samsung Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Grading of spoke-wheel sign on CEUS using sonazoid and SMI in patients with focal nodular hyperplasia a.To evaluate the detection rate of 'spoke-wheel sign' on CEUS using sonazoid and SMI (primary outcome).
Each US findings during exam for patients with FNH were recorded by radiologist. The results were interpreted by consensus using 4 scale bar.
0. Absence of 'spoke-wheel sign'
Mild suspicious of 'spoke-wheel sign'
Highly suspicious of 'spoke-wheel sign'
Definite "spoke-wheel sign'
1 day
Secondary Measurement error of focal nodular hyperplasia between b-mode US and SMI according to the reference standard, CEUS To calculate the measurement error between b-mode US and SMI using measurement of maximum diameter of tumor. Reference standard is the size of tumor on sonazoid enhanced US. 1 day
See also
  Status Clinical Trial Phase
Completed NCT02156700 - Quantitative Real-time Ultrasound Elastography for Characterisation of Liver Tumors N/A